Table 1

Baseline characteristics (ITT population)
All N = 35 Masitinib N = 27 Placebo N = 8
Age (years) Mean ± SD 48 ± 8 49 ± 9 47 ± 7
Min - Max 29–61 29–61 33–56
Weight (kg) Mean ± SD 69 ± 19 67 ± 19 74 ± 20
Min - Max 43–140 43–140 54–108
Male N (%) 17 (49) 13 (48) 4 (50)
Duration of disease (years) Mean ± SD 9.4 ± 7.4 9.5 ± 7.3 8.8 ± 8.4
Min - Max 0.2-28.6 0.2-28.6 1.5-25.6
MSFC score Mean ± SD 0.0 ± 0.7 -0.1 ± 0.7 0.3 ± 0.8
9-HPT (seconds) Mean ± SD 30 ± 9 30 ± 9 31 ± 12
PASAT-3” (correct answers) Mean ± SD 31 ± 15 30 ± 15 36 ± 15
T25FW* Mean ± SD N/A N/A N/A
EDSS score Mean ± SD 4.9 ± 1.2 4.9 ± 1.2 5.0 ± 1.1

* The baseline average of the raw (seconds) timed 25-foot walk test was not applicable (N/A) because of the protocol deviation (see text for details). MSFC = multiple sclerosis functional composite score. N = number of patients, intent-to-treat population. T25FW = timed 25-foot walk test. 9-HPT = nine ­hole peg test. PASAT-3” = Paced Auditory Serial Addition Test 3 seconds. EDSS = expanded disability status scale. ITT = intent-to-treat.

Vermersch et al.

Vermersch et al. BMC Neurology 2012 12:36   doi:10.1186/1471-2377-12-36

Open Data